ClinicalTrials.gg
CompletedNCT05269693Updated Apr 29, 2024

A BHI to Increase Hope Level and Stress Level of Parents With a CMC

An interventional study of Brief Hope Intervention in Child With Cancer, Muscular Atrophy, Spinal and Child With Cerebral Palsy, sponsored by The Hong Kong Polytechnic University. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2024-04-29.

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Sex
All
01

Study summary

Being a parent of a child with medical complexity (CMC) poses an enormous stress because these CMC have a multisystem disease, a severe neurologic condition or cancer which may result in premature death. Parents may feel challenged, lacking in confidence and high level of stress when managing their daily caregiving activities and child's new symptom. Literature suggested that hope is believed to be the central agent in facilitating positive psychological change when parents are facing difficulties and feeling stress. Brief Hope Intervention (BHI) is an alternative method considered to be feasible in improving parental hope level meanwhile, decreasing their stress level associated with daily caregiving activities. The purpose of BHI is to help these parents to develop workable goals, and concentrate on problem solving skill along with achievable planned actions in order to terminate the stressors associated from the caregiving activities.

This proposed pilot randomized controlled trial will test the feasibility and preliminary effect of the BHI in term of increasing the level of hope meanwhile decreasing the stress level of parents with a CMC. Eligibility, recruitment rates, and attrition rates will be collected in percentage to evaluate the feasibility of the study. Content analysis will be adopted to analysis the qualitative feedback on the acceptability of BHI from the parents. A repeated-measures, two-group design will be used to evaluate the preliminary effects between intervention and wait-listed control groups by comparing Brief Hope Intervention and wait-listed control groups receiving usual community care for 64 randomly selected parents over a 1-month follow-up. The outcome measures include parental hope and stress level. They will be measured before intervention, immediately after intervention and one-month after intervention.

With positive outcomes found in this study, this intervention will be implemented in a larger scale to improve local psychological health service for parents with a CMC.

02

Conditions studied

  • Child With Cancer
  • Muscular Atrophy, Spinal
  • Child With Cerebral Palsy
  • Endocrine System Diseases

Keywords

  • Brief Hope Therapy
  • Parent
  • Children with medical complexity
  • stress
03

In context

Muscular Atrophy, Spinal

294 studies on the registry are indexed under Muscular Atrophy, Spinal; 77 are open to participants now.

This study's enrollment of 40 is above the median of 27 across 165 interventional studies indexed under Muscular Atrophy, Spinal.

Browse Muscular Atrophy, Spinal studies →

Lead sponsor

The Hong Kong Polytechnic University is the lead sponsor of 676 studies on the registry; 254 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Parents of a CMC will be recruited via the special schools for the children with physical disabilities. The eligible criteria for parents are

  1. one of the parent of a child with medical complexity aged 5-18,
  2. able to communicate in Chinese and read Chinese,
  3. willing to participate in face-to-face activities and a telephone follow-up,
  4. alert and oriented, able to sustain approximately 1 hour of attention and interaction, and
  5. able to be reached by phone.

Exclusion criteria

Exclusion Criteria:

Parents are

  1. a reported mental health disorder,
  2. inability to communicate in Cantonese,
  3. engaging in other Hope Therapy related to stress relief and hope enhancement, and
  4. severe hearing deficit that prevented them from engaging in phone communication.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    the Brief Hope Intervention group

    The BHI consisted of 4 one-on-one sessions: 2 (1 hr) face- to-face sessions, and 2 (30 min) telephone follow-up sessions in-between.

    Other: Brief Hope Intervention

  • No intervention
    wait-listed control group

    Usual community care

Interventions

  • OtherBrief Hope Intervention

    The BHI consisted of 4 one-on-one sessions: 2 (1 hr) face- to-face sessions, and 2 (30 min) telephone follow-up sessions

06

What researchers measure

Primary outcomes

  1. Recruitment

    Enrollment and dropout rates will be calculated for each participant and summarized for all participants in the study

    Time frame: Week 4

  2. Intervention Delivery Rating Scale

    5-point Likert scale for evaluating the useful level of intervention, ranging from 1 (not at all) to 5 (most).Higher scores mean more better outcome.

    Time frame: Week 4

  3. Change of Hope Level

    State Hope Scale (Chinese version): consisting of 6 items. Each item is rated on a 8-point scale, with 1 = definitely false and 8 = definitely true. Higher scores mean higher hope level.

    Time frame: Week 0, Week 4, Week 8

  4. Change of Stress Level

    Perceived Stress Scale (Chinese version): consisting of 14 items. Each item is rated on a 5-point scale, ranging from 1 (not at all) to 5 (extremely). Higher scores mean higher stress level.

    Time frame: Week 0, Week 4, Week 8

07

Study locations

1 site
  • School of Nursing, The Hong Kong Polytechnic University
    Hong Kong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Feb 2023, 14 months.

Of 51 non-industry interventional studies with no phase under Muscular Atrophy, Spinal, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 51. This study's 14 months is below that.

Counting every sponsor, half of 60 studies reached it within 26 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2022
First posted
Mar 8, 2022
StartActual
Dec 1, 2021
Primary completionActual
Feb 1, 2023
CompletionActual
Feb 1, 2023
Last update
Apr 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05269693
Responsible party
Dr Winsome Lam (Assistant Professor, The Hong Kong Polytechnic University) — Principal investigator
First posted
Mar 8, 2022
Start date
Dec 1, 2021
Primary completion
Feb 1, 2023
Completion
Feb 1, 2023
Last update
Apr 29, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion